BioAge Labs, Inc.
HealthcareNASDAQ:BIOA · NASDAQ Global Select
+$1.59 today
Vol 0.44M · Avg 0.46M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-29.6%
avg 5.1%
ROIC
-33.4%
avg -152.5%
ROA
-27.3%
avg -108.3%
Analysis
ROA is currently the strongest return metric at -27.3% versus its period average of -108.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kristen Fortney | Co-Founder, Chief Executive Officer, President, Treasurer, Secretary & Director | $945,200.00 | — | 42 | $330,000.00 | 0.88% |
Paul D. Rubin | Chief Medical Officer & Executive Vice President of Research | $743,480.00 | — | 72 | $8,820.00 | 0.02% |
Eric Morgen | Co-Founder, Chief Operating Officer & Director | $714,640.00 | — | 43 | $110,000.00 | 0.29% |
Dov A. Goldstein | Chief Financial Officer | — | — | 59 | $155,833.00 | 0.41% |
Peng Leong | Chief Business Officer & Therapeutic Area Head of Brain Aging | — | — | — | — | — |
Sullivan | Chief Strategy Officer | — | — | — | — | — |
Ann C. Neale | Chief Development Officer | — | — | — | — | — |
Shane Barton | Senior Vice President of Finance & Accounting | — | — | 55 | $45,000.00 | 0.12% |
Rusty Montgomery | Senior Vice President of Research | — | — | — | — | — |
Julie Gammelgard | Senior Vice President of People | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
11
$6.22M
Net Sentiment
$6.22M
Net selling
Most Active
RUBIN PAUL D
6 transactions
1–10 of 11
Analysis
Insiders reported 0 buys worth $0.00 and 11 sells worth $6.22M over the last 12 months. That adds up to net selling of $6.22M. RUBIN PAUL D was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | +48.3% (5yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Forward estimates point to Revenue at +48.3% (5yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Cabaletta Bio, Inc.
NASDAQ:CABA
$490.79M
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$463.35M
Canopy Growth Corporation
NASDAQ:CGC
$425.84M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$359.32M
Editas Medicine, Inc.
NASDAQ:EDIT
$244.75M
Alpha Teknova, Inc.
NASDAQ:TKNO
$225.18M
Lifecore Biomedical, Inc.
NASDAQ:LFCR
$211.55M
Owens & Minor, Inc.
OMI
$207.07M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
Aurora Cannabis Inc.
NASDAQ:ACB
$172.40M
Who manages BIOA?
BioAge Labs, Inc. (BIOA) lists 10 active executives. The top listed executive is Dov A. Goldstein, Chief Financial Officer.
Are BIOA insiders buying or selling?
Recent insider activity shows net buying of $29.49M.
Explore More
Continue the stock analysis
Jump to another research area for this company.